胃肠胰神经内分泌肿瘤影像组学:系统综述与影像组学质量评分评估
该系统综述检索了PubMed、Embase和Wiley/Cochrane Library数据库,纳入45项关于胃肠胰神经内分泌肿瘤(GEP-NETs)的影像组学研究。多数研究聚焦于肿瘤分级和鉴别诊断,预测肿瘤分级与鉴别GEP-NETs的AUC分别为0.74-0.96和0.80-0.99;仅一项研究构建了胰腺NET复发预测模型(AUC 0.77)。纳入研究的平均影像组学质量评分(RQS)为18%。
要点
- GEP-NET影像组学证据主要集中在肿瘤分级和鉴别诊断,预测分级AUC 0.74-0.96,鉴别诊断AUC 0.80-0.99。
- 仅一项研究构建了胰腺NET复发预测模型,AUC为0.77。
- 纳入研究的平均RQS仅为18%,总体方法学质量偏低。
核心结论
- GEP-NET影像组学领域仍较新,已开发出一些有前景的模型,但预测治疗反应或长期结局的证据仍匮乏,未来研究应聚焦于构建稳健模型。
研究设计与样本
- 系统综述,检索PubMed、Embase和Wiley/Cochrane Library数据库并对纳入研究进行前后向参考文献核查,共识别1364项唯一研究,最终纳入45项分析;由两名评价者独立评估方法学质量(采用影像组学质量评分RQS)并提取结局数据;纳入标准为GEP-NETs患者及基于CT、MRI或PET的影像组学分析。
诊断标准与关键数值
- 预测肿瘤分级的AUC为0.74-0.96;鉴别GEP-NETs与其他肿瘤的AUC为0.80-0.99;预测胰腺NET复发的模型AUC为0.77;纳入研究的平均RQS为18%。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文指出GEP-NET影像组学领域仍较新,预测治疗反应或长期结局的证据仍匮乏。
- 原文指出未来研究应聚焦于构建稳健模型,文中认为该方向需进一步研究。
- 纳入研究的平均RQS仅为18%,原文指出多数GEP-NET影像组学研究质量偏低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The number of radiomics studies in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is rapidly increasing. This systematic review aims to provide an overview of the available evidence of radiomics for clinical outcome measures in GEP-NETs, to understand which applications hold the most promise and which areas lack evidence.
METHODS: PubMed, Embase, and Wiley/Cochrane Library databases were searched and a forward and backward reference check of the identified studies was executed. Inclusion criteria were (1) patients with GEP-NETs and (2) radiomics analysis on CT, MRI or PET. Two reviewers independently agreed on eligibility and assessed methodological quality with the radiomics quality score (RQS) and extracted outcome data.
RESULTS: In total, 1364 unique studies were identified and 45 were included for analysis. Most studies focused on GEP-NET grade and differential diagnosis of GEP-NETs from other neoplasms, while only a minority analysed treatment response or long-term outcomes. Several studies were able to predict tumour grade or to differentiate GEP-NETs from other lesions with a good performance (AUCs 0.74-0.96 and AUCs 0.80-0.99, respectively). Only one study developed a model to predict recurrence in pancreas NETs (AUC 0.77). The included studies reached a mean RQS of 18%.
CONCLUSION: Although radiomics for GEP-NETs is still a relatively new area, some promising models have been developed. Future research should focus on developing robust models for clinically relevant aims such as prediction of response or long-term outcome in GEP-NET, since evidence for these aims is still scarce.
KEY POINTS: • The majority of radiomics studies in gastroenteropancreatic neuroendocrine tumours is of low quality. • Most evidence for radiomics is available for the identification of tumour grade or differentiation of gastroenteropancreatic neuroendocrine tumours from other neoplasms. • Radiomics for the prediction of response or long-term outcome in gastroenteropancreatic neuroendocrine tumours warrants further research.
引用
- Staal, Aalbersberg, van der Velden, et al. GEP-NET radiomics: a systematic review and radiomics quality score assessment. Eur Radiol. 2022. PMID: 35882634. doi:10.1007/s00330-022-08996-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。